Bevacizumab-induced hypertension: pathogenesis and management. - Wikidata - wikimedia - TriplyDB

Bevacizumab-induced hypertension: pathogenesis and management.

Bevacizumab-induced hypertension: pathogenesis and management.

http://www.wikidata.org/entity/Q37882684

about

Personalized treatment for advanced colorectal cancer: KRAS and beyond Hypertension in patients with cancer Ovarian function following targeted anti-angiogenic therapy with bevacizumab Individualized therapy of HHT driven by network analysis of metabolomic profiles Therapeutic manipulation of angiogenesis with miR-27b Targeted therapies in colorectal cancer-an integrative view by PPPM Bevacizumab induced hypertension in gynecologic cancer: Does it resolve after completion of therapy?The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton.Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer.Antiangiogenic-induced hypertension: the molecular basis of signaling network.Antiangiogenic and anticancer molecules in cartilage.Identifiable hypertension: a new spectrum.Antiangiogenic agents in natural products for the treatment of gynecologic disorders.Bevacizumab: a review of its use in advanced cancer.Renal effects of targeted anticancer therapies.Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs).The safety of antiangiogenic agents and PARP inhibitors in platinum-sensitive recurrent ovarian cancer.MicroRNA miR-466 inhibits Lymphangiogenesis by targeting prospero-related homeobox 1 in the alkali burn corneal injury model.Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer.Clinical trial experience with CA4P anticancer therapy: focus on efficacy, cardiovascular adverse events, and hypertension management.Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with Bevacizumab, Gemcitabine and Cisplatin.Non-pharmacological interventions in patients with spinal cord compression: a systematic review.Adverse event grading following CTCAE v3.0 underestimates hypertensive side effects in patients with glioma treated with Bevacizumab.Current opinion on bevacizumab on endometrial cancer treatment.Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.Mechanisms, monitoring, and management of tyrosine kinase inhibitors-associated cardiovascular toxicities

P2860

Q26822817-FFA398D8-890B-4DAC-B6D2-A4D047ECFDFC Q27003980-8EC6C6A0-91EE-4163-A4EE-088B22D080E3 Q33748232-3290FF72-5C28-4022-ACDD-06A3B83D2CAC Q34106862-90B8EA90-A938-45BD-82C3-FA545BDF0D87 Q35835060-9E831C8E-2775-4EA6-9454-9E16A27D01C5 Q36646911-E5EA8939-EC24-45A6-82DB-BE71EF3F8148 Q37215966-53922614-4E9A-481F-847B-24CEB69B995B Q37418939-D614FC42-6752-4211-A8C2-DF9E56F41798 Q37697540-3DA2F11B-FB2F-4F02-8C61-08634EC064B6 Q37973600-77740052-5DC1-4966-8E90-4D8B244E10E5 Q38007565-999B8ADB-90CC-43F3-9718-E0E53E0C1458 Q38148619-F33269F5-BBB9-4445-80AE-380319B2D321 Q38177316-01EABA3C-E360-4889-9E52-F43BB2B5671B Q38260176-162BCBE9-DAE4-468A-BD94-9DE6D718356B Q38367168-C0D7C26F-B3CA-4850-967A-7EDAF248EDD1 Q38827793-4637F3AE-BBEC-4B49-9085-7718B082BCE1 Q39282981-C57FE8EC-E3A5-4750-A336-4C1184DA8314 Q41602657-CE0C535E-A2E5-4B38-B832-1D31D9B385C7 Q43203308-066D150E-1858-4045-A8E2-729784346730 Q47218543-6222D54A-121C-405E-AB4F-DA6D331F5E0B Q47566245-628C9D51-01CF-43D7-BAD6-E338EEE5B10C Q48153788-359435D8-3509-4ACE-871D-8EC1FAFEDFEE Q48265679-6CC8045C-BBFA-4621-B9D6-4408943557DB Q49066603-9AADFAD3-6340-4047-860A-5A84D88149A5 Q53225923-C482D288-4112-453F-AB35-2A5E221AADC9 Q54969682-FAD47A60-6F6D-4E8F-A6B5-FCED50A9F7C3 Q57069976-AF3D2B64-46D0-4E85-AA7E-3054D3045DC5

P2860

Bevacizumab-induced hypertension: pathogenesis and management.

http://www.wikidata.org/entity/Q37882684

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2011

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Bevacizumab-induced hypertension: pathogenesis and management.

@en

Bevacizumab-induced hypertension: pathogenesis and management.

@nl

type

label

Bevacizumab-induced hypertension: pathogenesis and management.

@en

Bevacizumab-induced hypertension: pathogenesis and management.

@nl

prefLabel

Bevacizumab-induced hypertension: pathogenesis and management.

@en

Bevacizumab-induced hypertension: pathogenesis and management.

@nl

P1433

Q37882684-16EA4BAB-0EA4-4A02-9753-2436F0699D55

P1476

Q37882684-23D4B4AA-1B8F-4D2E-A072-5FC946437A4C

P2093

Q37882684-2B4BA1EF-CE66-4B9E-9980-DF03D4F5BCC6

Q37882684-41A0050A-44FA-4840-B1BB-7D8FA08EF9EB

Q37882684-5CC721E3-86D3-4A58-A3D5-39E5364743E3

Q37882684-68FF7E41-48F8-4437-9C99-18892C5701AA

Q37882684-8FD2CE0E-9DB5-44C9-8071-792AFFFD00B7

P2860

Q37882684-0CD22F86-5D67-4AB2-98F0-FC5A569F09E5

Q37882684-0F7D7DAD-C477-4A3F-8E5F-D8AF3339F7CB

Q37882684-128D3812-8CFB-48A5-8911-D647213258B0

Q37882684-13FB8664-D1A9-494D-8B14-0CCB54BA71BE

Q37882684-2E705FEB-0454-4B67-8501-68DF9AD3D260

Q37882684-2EFCE6D2-EBF4-4F0D-A65D-9C3CCAFB8067

Q37882684-331657B0-745D-4203-B478-1CD8168E0000

Q37882684-34C6781A-5300-437B-AD66-CD29C38BBA5F

Q37882684-350881AE-DC1C-4CE3-B3BC-D3AAF6B99A4C

Q37882684-3C92B7F6-77EA-4360-8149-DA30406100C9

P2888

Q37882684-4BD76041-1260-411C-BA03-1D5F465FF12B

P304

Q37882684-3A1DA3CF-EA14-4C15-B263-0D887A1DF079

P31

Q37882684-24AA9FF8-1871-483F-8DB5-619EC3BC83B4

P356

Q37882684-99035C4A-4D7C-4D46-84D2-744145F1C46F

P433

Q37882684-96EC6EDD-ACB5-47FA-B9E4-C24693A2A907

P478

Q37882684-D4202930-FA9C-43E1-A458-9FABEA82FF5D

P577

Q37882684-EF6129F1-893B-42B2-BA66-B434342BE8A2

P5875

Q37882684-0D180168-0B1C-4441-BF25-B467516D2759

P698

Q37882684-3D22862A-EFA8-48B9-BBF8-DA1B15031706

P921

Q37882684-90CAA8D6-9CEE-4050-BCB9-83655B8893CA

Q37882684-9DCBD195-3E76-441D-85A4-A7F7C8796A25

Q37882684-A8E9EB5E-49B8-4F87-8C5B-0C78B2D92528

P356

11590180-000000000-00000

P1433

P1476

Bevacizumab-induced hypertension: pathogenesis and management.

@en

P2093

Christian Manegold

http://www.w3.org/2001/XMLSchema#string

Eleni Karapanagiotou

http://www.w3.org/2001/XMLSchema#string

Kevin Harrington

http://www.w3.org/2001/XMLSchema#string

Kostas N Syrigos

http://www.w3.org/2001/XMLSchema#string

Paraskevi Boura

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

The biology of VEGF and its receptors

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

Angiogenic factors

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer.

P2888

11590180-000000000-00000

P304

159-169

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11590180-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

25

http://www.w3.org/2001/XMLSchema#string

P577

2011-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51179233

http://www.w3.org/2001/XMLSchema#string

P698

21627340

http://www.w3.org/2001/XMLSchema#string

P921

arterial hypertension